Randall Hawkins, MD, PhD


Academic Title



UC Irvine School of Medicine 1975


University of Southern California, Radiology 1979


UCLA Medical Center, Nuclear Medicine 1981

Selected Research and Publications

  1. Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D'Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J, Negrin R, Gambhir SS. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res. 2017 Jun 01; 77(11):2893-2902.
  2. Arentson-Lantz EJ, Saeed IH, Frassetto LA, Masharani U, Harnish RJ, Seo Y, VanBrocklin HF, Hawkins RA, Mari-Aparici C, Pampaloni MH, Slater J, Paddon-Jones D, Lang TF. 11C-L-methyl methionine dynamic PET/CT of skeletal muscle: response to protein supplementation compared to L-[ring 13C6] phenylalanine infusion with serial muscle biopsy. Ann Nucl Med. 2017 May; 31(4):295-303.
  3. Franc BL, Goth S, MacKenzie J, Li X, Blecha J, Lam T, Jivan S, Hawkins RA, VanBrocklin H. In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis. Mol Imaging. 2017 Jan 01; 16:1536012117712638.
  4. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874.
  5. Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 Feb 01; 97(2):270-277.
  6. Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines. 2016 Oct 31; 4(4).
  7. Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, VanBrocklin HF, Goadsby PJ. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 2016 Jul; 139(Pt 7):1994-2001.
  8. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75.
  9. Monteith TS, Kralik SF, Dillon WP, Hawkins RA, Goadsby PJ. The utility of radioisotope cisternography in low CSF/volume syndromes compared to myelography. Cephalalgia. 2016 Jan 27.
  10. Kleis MA, Daldrup-Link H, Goldsby R, Hawkins RA, Franc BL. Multiple Scalp Lesions in a Patient with Keratitis, Ichthyosis and Deafness Syndrome Mimicking Metastatic Squamous Cell Carcinoma on 18F-FDG PET/CT. Radiol Case Rep. 2009; 4(2):218.
  11. Aparici CM, Bains SN, Carlson D, Qian J, Liou D, Wojciechowski D, Werner J, Khan S, Kroll C, Sandhu M, Nguyen N, Hawkins R. Recovery of Native Renal Function in Patients with Hepatorenal Syndrome Following Combined Liver and Kidney Transplant with Mercaptoacetyltriglycine-3 Renogram: Developing a Methodology. World J Nucl Med. 2016 Jan-Apr; 15(1):44-9.
  12. Flavell RR, Naeger DM, Aparici CM, Hawkins RA, Pampaloni MH, Behr SC. Malignancies with Low Fluorodeoxyglucose Uptake at PET/CT: Pitfalls and Prognostic Importance: Resident and Fellow Education Feature. Radiographics. 2016 Jan-Feb; 36(1):293-4.
  13. Lee JS, Wu R, Wong T, DuBois SG, Matthay K, Gustafson C, Hawkins R, Roy-Burman A. Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):471-8.
  14. Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42.
  15. Wagstaff J, Jones R, Hawkins R, Porfiri E, Pickering L, Bahl A, Brown J, Buchan S. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol. 2016 Jan; 27(1):159-65.
  16. Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y. Patient-specific dosimetry using pretherapy [4I]m-iodobenzylguanidine ([4I]mIBG) dynamic PET/CT imaging before [I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015 Apr; 17(2):284-94.
  17. Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361.
  18. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21.
  19. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81.
  20. DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015 Feb 17; 112(4):644-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.